It usually comes up right after someone hits a plateau. A client who’s been grinding through their program for months, doing everything right, and still not seeing the scale move the way they want. Then: “My cousin’s on this new shot, retatrutide, way stronger than Ozempic. Should I look into it?”
A year ago, this was semaglutide. Then tirzepatide. Now it’s retatrutide, and the pattern tracks almost exactly how SERMs and TRT alternatives worked their way from niche forums into completely ordinary conversations at the gym. Clients read a headline, see a number, and bring it straight to the person they trust most with their body: you.
Here’s what the science actually says, what your certification does and doesn’t cover, and where the conversation should go instead.
What Retatrutide Actually Is
Retatrutide is an investigational compound developed by Eli Lilly, currently identified in the research literature by its development code, LY3437943. Structurally, it’s designed to act on three separate receptors at once: GLP-1, GIP, and the glucagon receptor. That third target is what separates it from the two GLP-1-based drugs your clients have probably already heard of.
Cell culture research indicates retatrutide is less active than the body’s own signaling molecules at the glucagon and GLP-1 receptors, while being considerably more potent at the GIP receptor.
In plain terms: it’s engineered to hit all three appetite- and metabolism-related pathways simultaneously, rather than relying on just one or two.
It is not approved by the U.S. Food and Drug Administration for any use. It is currently studied strictly within clinical trial settings and is not available as a prescribed medication in the United States.
What the Trials Have Actually Shown So Far
A phase 2 trial published in the New England Journal of Medicine found that 48 weeks of treatment with retatrutide, an agonist of the GIP, GLP-1, and glucagon receptors, produced substantial reductions in body weight among participants with obesity.
Later analysis of that same trial population also looked beyond the scale: investigators observed improvements in liver fat and related biomarkers in a substudy focused on participants with fatty liver disease.
Those are meaningful findings; that’s exactly why researchers keep studying this compound. But a few things are worth being precise about when a client brings this up:
- These are trial results from a controlled research population, monitored by clinical staff, not real-world outcomes for someone self-administering an unregulated product.
- The dose-response relationships governing this compound’s side effects, safety, and efficacy for obesity treatment are, in the researchers’ own words, not yet known.
- Phase 3 trials are still ongoing. Research findings at this stage are not the same thing as an approved, prescribable treatment.
That gap between “promising in a monitored trial” and “appropriate for a client to use on their own” is the whole conversation in a nutshell.
The Side of the Research Nobody’s Excited to Talk About
The most frequently reported adverse events in the phase 2 trial were transient gastrointestinal effects, occurring mostly during the dose-escalation phase and more often at higher dose levels.
Researchers also tracked cardiovascular measures: heart rate increased with treatment in a dose-dependent pattern, peaking around week 24 before declining later in the trial.
None of this means the compound is unsafe in a monitored research context; it means it’s actively being studied for exactly these reasons. It also means nobody, including a personal trainer, should be waving a client toward it as though the safety profile is settled science. It isn’t, by the trial authors’ own account.
Where Your Certification Ends
This is the paragraph worth reading twice.
Advising a client on whether to pursue an investigational, non-FDA-approved compound isn’t something any personal training certification qualifies you to do—not Fitness Mentors, NASM, not ACE, not ISSA, not any of them.
That’s a medical decision that belongs with a licensed physician who can review labs, medical history, and the client’s full health picture. Stepping into that territory, even with good intentions, puts your client at real risk and puts your business at real liability.
That doesn’t mean you go silent when the topic comes up. It means the honest answer sounds something like:
“That’s a question for your doctor. They can look at your bloodwork and your full picture. What I can help you dial in right now is the training and nutrition side, and that’s the stuff that actually compounds over time, no matter what else you do.”
Then deliver on that second half.
What Actually Moves the Needle in the Meantime
Plateaus are frustrating, and “there’s a shot for that” is an appealing story. But the fundamentals you’re already trained to coach—progressive overload, adequate protein, a sustainable caloric deficit, sleep, and consistency over months rather than weeks—are still what determines whether a client keeps results long term, regardless of anything else they add on top.
A client who nails those basics is in a completely different position than one hoping an unregulated compound does the work for them.
Trainers who stay informed about emerging options like Retatrutide for weight loss research are better equipped to guide conversations productively while staying within their professional scope.
The Bottom Line
Retatrutide is a legitimate, closely watched subject of clinical research, a triple-receptor compound with real trial data behind it. It is also not an approved medication, not something within a trainer’s scope to guide a client toward, and not something with a settled long-term safety picture even in the populations studied so directly.
Your job isn’t to have zero opinion when a client brings it up. It’s to know enough to speak to it accurately, point them toward the physician who’s actually qualified to advise them, and keep them anchored to the training fundamentals that were never going anywhere.
Clients occasionally mention sourcing research peptides from online vendors such as Purerawz, which further highlights why trainers must stay firmly within their scope and redirect these conversations to medical professionals.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972
- Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. PMC11271400.
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active comparator-controlled phase 2 trial. The Lancet. 2023;402(10401):529-544. DOI: 10.1016/S0140-6736(23)01053-X
